In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer
Abstract
The complex tumor microenvironment (TME) presents significant challenges to the development of effective therapies against solid tumors, highlighting the need for advanced in vitro models that better recapitulate TME biology. To address this, we developed a vascularized human liver tumor model using a microfluidic platform, designed to test both drug and cell-based therapies. This model mimics critical tumorigenic features such as hypoxia, extracellular matrix (ECM), and perfusable vascular networks. Intravascular administration of Sorafenib demonstrated its ability to disrupt vascular structures significantly, while eliciting heterogeneous responses in two distinct liver tumor cell lines, HepG2 and Hep3b. Furthermore, treatment with engineered T-cells revealed that the tumor vasculature impeded T-cell infiltration into the tumor core but preserved their cytotoxic capacity, albeit with reduced exhaustion levels. Cytokine analysis and spatial profiling of vascularized tumor samples identified proinflammatory factors that may enhance T-cell-mediated antitumor responses. By capturing key TME characteristics, this microfluidic platform provides a powerful tool enabling detailed investigation of tumor-immune and tumor-vascular interactions. Its versatility could serve as a promising bridge between preclinical studies and clinical testing, offering opportunities for developing and optimizing personalized therapeutic strategies for solid tumors. • Developed an in vitro model of a human liver tumor integrated with a functional vasculature within a microfluidic platform. • Sorafenib disrupted tumor vasculature and induced heterogenous responses in different liver tumor subtypes. • Tumor vasculature reduced the infiltration of engineered T-cells but preserved its cytotoxic capacity. • Spatial profiling of the tumor microenvironment revealed activation and exhaustion patterns in engineered T-cells.
Related
- Evidence for early kidney vasculature development by vasculogenesis and angiogenesis based on advanced in vivo chimeric model and depletion of CD31+/CD146+ intrinsic endothelial progenitors
- Brain microvascular endothelial cell dysfunction during Plasmodium infection does not result from astrocyte-derived wingless-related integration site (Wnt)7a deficiency
- Transient Vascular Cell Integration and Intrinsic Media-Stimulated Endothelial Activation Reveal Diabetic Retinopathy Signatures in Human Retinal Organoids
- ORGANOTYPIC ENDOTHELIAL IDENTITY DETERMINES DIVERGENT MOLECULAR AND FUNCTIONAL RESPONSES TO LPS AND IL-6
- From TLS architecture to functional immune niches: division of labor among CAFs, HEVs, and antigen-presenting cells in cancer immunotherapy
BibTeX
@article{vasudevan2026vitro,
title = {{In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer}},
author = {Jyothsna Vasudevan and Ragavi Vijayakumar and Jose Antonio Reales-Calderon and Maxine S.Y. Lam and Jin Rong Ow and Joey Aw and Damien Tan and Anthony Tanoto Tan and Antonio Bertoletti and Giulia Adriani and Andrea Pavesi},
journal = {Biomaterials},
year = {2026},
month = oct,
doi = {10.1016/j.biomaterials.2025.123175},
url = {https://hal.science/hal-05776447v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer
AU - Jyothsna Vasudevan
AU - Ragavi Vijayakumar
AU - Jose Antonio Reales-Calderon
AU - Maxine S.Y. Lam
AU - Jin Rong Ow
AU - Joey Aw
AU - Damien Tan
AU - Anthony Tanoto Tan
AU - Antonio Bertoletti
AU - Giulia Adriani
AU - Andrea Pavesi
PY - 2026
DA - 2026/10/03
JO - Biomaterials
DO - 10.1016/j.biomaterials.2025.123175
UR - https://hal.science/hal-05776447v1
AB - The complex tumor microenvironment (TME) presents significant challenges to the development of effective therapies against solid tumors, highlighting the need for advanced in vitro models that better recapitulate TME biology. To address this, we developed a vascularized human liver tumor model using a microfluidic platform, designed to test both drug and cell-based therapies. This model mimics critical tumorigenic features such as hypoxia, extracellular matrix (ECM), and perfusable vascular networks. Intravascular administration of Sorafenib demonstrated its ability to disrupt vascular structures significantly, while eliciting heterogeneous responses in two distinct liver tumor cell lines, HepG2 and Hep3b. Furthermore, treatment with engineered T-cells revealed that the tumor vasculature impeded T-cell infiltration into the tumor core but preserved their cytotoxic capacity, albeit with reduced exhaustion levels. Cytokine analysis and spatial profiling of vascularized tumor samples identified proinflammatory factors that may enhance T-cell-mediated antitumor responses. By capturing key TME characteristics, this microfluidic platform provides a powerful tool enabling detailed investigation of tumor-immune and tumor-vascular interactions. Its versatility could serve as a promising bridge between preclinical studies and clinical testing, offering opportunities for developing and optimizing personalized therapeutic strategies for solid tumors. • Developed an in vitro model of a human liver tumor integrated with a functional vasculature within a microfluidic platform. • Sorafenib disrupted tumor vasculature and induced heterogenous responses in different liver tumor subtypes. • Tumor vasculature reduced the infiltration of engineered T-cells but preserved its cytotoxic capacity. • Spatial profiling of the tumor microenvironment revealed activation and exhaustion patterns in engineered T-cells.
SN - 1878-5905
ER -